Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 4/20 | 0.81 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16910242 | 0.93 | SIGMAR1 (0.69) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| Triparanol SCHEMBL133384 | 0.89 | EBP (1.00) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL7753432 | 0.89 | SIGMAR1 (0.79) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL330094 | 0.86 | SIGMAR1 (0.67) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL10878286 | 0.85 | EBP (0.72) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL8707721 | 0.83 | EBP (0.60) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| Triparanol SCHEMBL5488333 | 0.83 | EBP (0.86) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL10356744 | 0.81 | CYP2D6 (0.58) | EBPSIGMAR1CYP2D6HTTCYP1A2 | |
| SCHEMBL4746221 | 0.81 | EBP (0.54) | EBPSIGMAR1HTTHRH3DRD3 | |
| SCHEMBL10358944 | 0.79 | EBP (0.62) | EBPSIGMAR1CYP2D6HTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511070-B2 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | PONIARD PHARMACEUTICALS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-0833624-B1 | PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES WITH TAMOXIFEN ANALOGUES | PONIARD PHARMACEUTICALS INC (US) | 2007-11-07 | — | — | EP | disclosed |
| US-7094550-B2 | Method to determine TGF-beta | NEORX CORPORATION (US) | 2006-08-22 | — | — | US | disclosed |
| US-7084171-B2 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | NEORX CORPORATION (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060135560-A1 | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues | NEORX CORPORATION | 2006-06-22 | — | — | US | disclosed |
| US-20060084696-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | PONIARD PHARMACEUTICALS, INC. | 2006-04-20 | — | — | US | disclosed |
| US-20060029986-A1 | Prevention and treatment of cardiovascular pathologies | PONIARD PHARMACEUTICALS, INC. | 2006-02-09 | — | — | US | disclosed |
| US-20050020667-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | PONIARD PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | disclosed |
| US-6734208-B2 | ADJUSTMENT TRANSFORMING GROWTH FACTOR CONCENTRATION; ANTIINFLAMMATORY AGENTS | NEORX CORPORATION | 2004-05-11 | — | — | US | disclosed |
| US-20030064970-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | NEORX CORPORATION | 2003-04-03 | — | — | US | disclosed |
| US-6251920-B1 | ADMINISTERING TAMOXIFEN OR ITS STRUCTURAL ANALOGS FOR PROPHYLAXIS AND THERAPY OF ATHEROSCLEROSIS, THROMBOSIS, MYOCARDIAL INFARCTION AND STROKE | NEORX CORPORATION | 2001-06-26 | — | — | US | disclosed |
| US-6197789-B1 | ANTIDIABETIC AGENTS | NEORX CORPORATION | 2001-03-06 | — | — | US | disclosed |
| US-6117911-A | ADMINISTRATION OF AT LEAST ONE THERAPEUTIC AGENT THAT ELEVATES THE LEVEL OF TGF-BETA IN SAID MAMMAL. | NEORX CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| WO-1998046588-A2 | COMPOUNDS AND THERAPIES FOR THE PREVENTION OF VASCULAR AND NON-VASCULAR PATHOLOGIES | NEORX CORPORATION (US) | 1998-10-22 | — | — | WO | disclosed |
| EP-0833624-A2 | PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES WITH TAMOXIFEN ANALOGUES | NEORX CORPORATION (US) | 1998-04-08 | — | — | EP | disclosed |
| US-5595722-A | TRANSFORMING GROWTH FACTOR-BETA ACTIVATORS | NEORX CORPORATION (US) | 1997-01-21 | — | — | US | disclosed |
| WO-1996040098-A2 | PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES WITH TAMOXIFEN ANALOGUES | NEORX CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5030417-A | Method and kit to assay for steroid receptor functionality in cancerous cells | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1991-07-09 | — | — | US | disclosed |
| US-4806464-A | Nuclear binding assay for steroid receptor functionality in cancerous cells | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1989-02-21 | — | — | US | disclosed |
| WO-1988008537-A1 | KIT FOR ASSAYING STEROID RECEPTOR FUNCTIONALITY IN CANCEROUS CELLS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1988-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084696-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | TGFB1, TGFB2, TEK | EBP 64/4885SIGMAR1 3998/4885CYP2D6 4879/4885 |
| US-20060135560-A1 | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues | TGFB1, TGFB2, TNNI3 | EBP 312/4885SIGMAR1 2434/4885CYP2D6 2203/4885 |
| US-20050020667-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | TGFB1, TGFB2, TEK | EBP 64/4885SIGMAR1 3998/4885CYP2D6 4879/4885 |
| US-20030064970-A1 | Compounds and therapies for the prevention of vascular and non-vascular pathologies | TGFB1, TGFB2, TEK | EBP 64/4885SIGMAR1 3998/4885CYP2D6 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.